Tenon Medical, Inc. · NASDAQ:TNON
Tenon Medical — Q2 2026 Earnings Presentation
6 slides from Tenon Medical's earnings presentation, Aug 13, 2026
Slide 1: Tenon Medical Reports First Quarter 2026 Financial Results
Tenon® Medical Reports First Quarter 2026 Financial Results ~ First Quarter 2026 Revenue of $1.4 Million, an Increase of Approximately 90% Compared to Prior Year ~ ~ First Quarter Gross Profit of $0.9 Million, an Increase of Approximately 193% Compared to Prior Year ~ ~ Gross Margin Expanded Approxi
Slide 2: First Quarter 2026 Financial Results
growth across both Catamaran® and SImmetry®+, expand our base of trained surgeons, and maintain the disciplined cost structure that is now showing through in our gross margin and field productivity. With a differentiated multi- approach portfolio, a strengthened balance sheet, and the capital flexib
Slide 3: About Tenon Medical, Inc.
About Tenon Medical, Inc. Tenon Medical, Inc. is a medical device company founded in 2012 and committed to developing novel technologies for patients suffering from debilitating SI joint pain and dysfunction. The Company markets the Catamaran® and SImmetry+® SI Joint Fusion Systems, which offer a no
Slide 4: Condensed Balance Sheets (Unaudited)
tenon@mzgroup.us Tenon Medical, Inc. Condensed Balance Sheets (Unaudited) (In thousands, except share data) March 31, December31, 2026 2025 ASSETS Current assets: $ 4,607 $ 3,756 Cash and cash equivalents 1,969 1,698 Accounts receivable, net 806 1,054 Inventory 238 260 Prepaid expenses and other cur
Slide 5: Condensed Statements of Operations and Comprehensive Loss (Unaudited)
Stockholders' equity: Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at March 31, 2026 and December 31, 2025; 204,159 shares issued and outstanding at March 31, 2026 and December 31, 2025 2,622 2,622 Series B convertible preferred stock, $0.001 par value; 491,222
Slide 6: Condensed Statements of Operations (Unaudited)
Three Months Ended March 31, 2026 2025 $ 1,379 $ 726 Revenue 434 403 Cost of revenue 945 323 Gross Profit Operating Expenses 662 691 Research and development 1,858 1,647 Sales and marketing 1,705 1,662 General and administrative 4,225 4,000 Total Operating Expenses (3,280 ) (3,677 ) Loss from Operat